ArticleRespiratory research2022
Acute exacerbation of rheumatoid arthritis-associated interstitial lung disease: mortality and its prediction model.
Article in Respiratory research, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- BAL lymphocytosis as a predictive marker for drug response and long-term outcome in fibrotic ILD: systematic review.BMJ open respiratory research · 2026Pooled it
- Incidence, risk factors, and prognosis of acute exacerbation of rheumatoid arthritis-associated interstitial lung disease: a systematic review and meta-analysis.BMC pulmonary medicine · 2023Pooled it
- Effect of nintedanib in patients with progressive pulmonary fibrosis associated with rheumatoid arthritis: data from the INBUILD trial.Clinical rheumatology · 2023Trial
- Review
- Efficacy of Janus kinase inhibitors in the treatment of acute exacerbations of rheumatoid arthritis-associated interstitial lung disease: a retrospective observational case series.Frontiers in immunology · 2026Observational
- Development and internal validation of a prediction model for rheumatoid arthritis: a case-control study.Scientific reports · 2025Article
- Radiological extent predicts prognosis and relapse after acute exacerbation of interstitial lung disease in patients with rheumatoid arthritis: KEIO-RA-cohort.Rheumatology international · 2025Article
- Systemic autoimmune rheumatic diseases-associated interstitial lung disease: a pulmonologist's perspective.Breathe (Sheffield, England) · 2025Review
- AORI-HAP: a multidimensional risk index to predict in-hospital adverse outcomes in asthma exacerbations.Frontiers in medicine · 2025Article
- Potential of phosphodiesterase 4B inhibitors in the treatment of interstitial lung disease associated with autoimmune diseases.Clinical and experimental rheumatology · 2025Review
- Clinical Course of Interstitial Lung Disease in Patients With Rheumatoid Arthritis.ACR open rheumatology · 2024Review
- Acute exacerbations in patients with progressive pulmonary fibrosis.ERJ open research · 2024Article
- Acute exacerbation of interstitial lung disease after transthoracic biopsy.Jornal brasileiro de pneumologia : publicacao oficial da Sociedade Brasileira de Pneumologia e Tisilogia · 2024Article
- A Systematic Review of the Key Predictors of Progression and Mortality of Rheumatoid Arthritis-Associated Interstitial Lung Disease.Diagnostics (Basel, Switzerland) · 2024Review
- Acute exacerbation of idiopathic pulmonary fibrosis disease: a diagnosis model in China.European journal of medical research · 2024Article
- Rituximab for the treatment of acute exacerbation of interstitial lung disease associated with connective tissue disease.RMD open · 2023Article
- Clinical prediction models of rheumatoid arthritis and its complications: focus on cardiovascular disease and interstitial lung disease.Arthritis research & therapy · 2023Review
- Re-hospitalisation predicts poor prognosis after acute exacerbation of interstitial lung disease.BMC pulmonary medicine · 2023Article
- Unmet needs and perspectives in rheumatoid arthritis-associated interstitial lung disease: A critical review.Frontiers in medicine · 2023Review
- Acute exacerbation of rheumatoid arthritis-associated interstitial lung disease triggered by COVID-19: What is the best practice for treatment?Respiratory medicine case reports · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPatients with rheumatoid arthritis-associated interstitial lung disease (RA-ILD), like those with idiopathic pulmonary fibrosis (IPF), might develop an unexpected acute exacerbation (AE)-a rapidly progressing and deadly respiratory decline. Although AE incidence and risk factors in RA-ILD patients are known, their post-AE clinical course remains unknown owing to the rarity of AE-RA-ILD. This multicentre retrospective study evaluated post-AE mortality and prognostic variables in AE-RA-ILD patients and created a mortality prediction model for AE-RA-ILD.
methodsThis research comprised 58 patients with AE-RA-ILD and 96 with AE-IPF (a control disease). Multivariate Cox regression analysis was performed to identify prognostic variables. A prediction model was created with recursive partitioning (decision tree).
resultsThe post-AE 90-day mortality rate in the overall AE-RA-ILD group was 48.3%; percent predicted forced vital capacity within 12 months before AE onset (baseline %FVC) and PaO
conclusionsPost-AE mortality was high in AE-RA-ILD patients similar to AE-IPF patients. The discovered prognostic factors and our mortality prediction model may aid in the management of AE-RA-ILD patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.